In line with this evidence, strategies aimed at restoring an efficient Nrf2 activation are considered promising therapeutic approaches (Petrillo et al., 2019) and several drugs have been proposed which restore appropriate Nrf2 response in FRDA cellular and animal models. The gene discussed is NFE2L2; the disease is Friedreich ataxia.